A Prospective Study of Direct-acting Antiviral Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort

Background And Aims: Mixed cryoglobulinemia is the most common HCV extrahepatic manifestation. We aimed to prospectively evaluate the cryoglobulinemic vasculitis (CV) clinical profile after a sustained virologic response (SVR) over a medium-term to long-term period.

Approach And Results: Direct-acting antiviral-treated cryoglobulinemic patients, consecutively enrolled in the multicentric Italian Platform for the Study of Viral Hepatitis Therapy cohort, were prospectively evaluated. Cumulative incidence Kaplan-Meier curves were reported for response, clinical deterioration, relapse and relapse-free survival rates. Cox regression analysis evaluated factors associated with different outcomes. A clinical response was reported in at least one follow-up point for 373 of 423 (88%) patients with CV who achieved SVR. Clinical response increased over time with a 76% improvement rate at month 12 after the end of treatment. A full complete response (FCR) was reached by 164 (38.8%) patients in at least one follow-up point. CV clinical response fluctuated, with some deterioration of the initial response in 49.6% of patients (median time of deterioration, 19 months). In patients who achieved FCR and had an available follow-up (137 patients) a relapse was observed in 13% and it was transient in 66.7% of patients. The rate of patients without any deterioration was 58% and 41% at 12 and 24 months, respectively. After achieving SVR, a clinical nonresponse was associated with older age and renal involvement; a clinical deterioration/relapse was associated with high pretreatment rheumatoid factor values, and FCR was inversely associated with age, neuropathy, and high cryocrit levels.

Conclusion: In patients with CV, HCV eradication may not correspond to a persistent clinical improvement, and clinical response may fluctuate. This implies an attentive approach to post-SVR evaluation through prognostic factors and tailored treatment.

Citing Articles

Hepatitis C associated mixed cryoglobulinemia glomerulonephritis in the setting of undetectable viral load: successful treatment with hydroxychloroquine and review of the literature.

Shweikeh F, Torres Y, Khan K, Mouchli M, Singh I Immunol Res. 2025; 73(1):55.

PMID: 39979644 DOI: 10.1007/s12026-025-09608-7.

Long-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy.

Mennini F, Sciattella P, Simonelli C, Marcellusi A, Rosato S, Kondili L J Viral Hepat. 2025; 32(2):e14061.

PMID: 39868676 PMC: 11771735. DOI: 10.1111/jvh.14061.

Surface antigen serocleared hepatitis B virus infection increases the risk of mixed cryoglobulinemia vasculitis in male patients with chronic hepatitis C.

Morrone A, Fiorilli V, Cinti L, Roberto P, Ferri A, Visentini M Front Immunol. 2024; 15:1411146.

PMID: 39055707 PMC: 11269149. DOI: 10.3389/fimmu.2024.1411146.

Clinical characteristics, radiological features and outcomes in pulmonary involvement of cryoglobulinemia.

Han H, Su W, Tian X, Zhou D, Li J, Cao X Orphanet J Rare Dis. 2024; 19(1):185.

PMID: 38698461 PMC: 11067141. DOI: 10.1186/s13023-024-03159-0.

Chronic Hepatitis C Virus Infection, Extrahepatic Disease and the Impact of New Direct-Acting Antivirals.

Mendez-Sanchez N, Coronel-Castillo C, Ramirez-Mejia M Pathogens. 2024; 13(4).

PMID: 38668294 PMC: 11053783. DOI: 10.3390/pathogens13040339.

References

Kondili L, Gaeta G, Brunetto M, Di Leo A, Iannone A, Santantonio T . Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017; 12(10):e0185728. PMC: 5627924. DOI: 10.1371/journal.pone.0185728. View

Zignego A, Giannini C, Gragnani L . HCV and lymphoproliferation. Clin Dev Immunol. 2012; 2012:980942. PMC: 3407626. DOI: 10.1155/2012/980942. View

Ramos-Casals M, Stone J, Cid M, Bosch X . The cryoglobulinaemias. Lancet. 2011; 379(9813):348-60. DOI: 10.1016/S0140-6736(11)60242-0. View

Kondili L, Vella S, Zignego A . Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice. Liver Int. 2017; 38(1):183. DOI: 10.1111/liv.13490. View

Cacoub P, Saadoun D . Extrahepatic Manifestations of Chronic HCV Infection. N Engl J Med. 2021; 384(11):1038-1052. DOI: 10.1056/NEJMra2033539. View

Galli M, Oreni L, Saccardo F, Castelnovo L, Filippini D, Marson P . HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). Clin Exp Rheumatol. 2017; 35 Suppl 103(1):67-76. View

Meltzer M, FRANKLIN E, Elias K, McCluskey R, Cooper N . Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med. 1966; 40(6):837-56. DOI: 10.1016/0002-9343(66)90200-2. View

Roy A, Dhiman R . Letter to the Editor: Recurrent Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antivirals: A Story Beyond Sustained Virological Response 12. Hepatology. 2021; 74(5):2909. DOI: 10.1002/hep.31860. View

Cacoub P, Si Ahmed S, Ferfar Y, Pol S, Thabut D, Hezode C . Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. Clin Gastroenterol Hepatol. 2018; 17(3):518-526. DOI: 10.1016/j.cgh.2018.05.021. View

10.

Desbois A, Cacoub P, Saadoun D . Cryoglobulinemia: An update in 2019. Joint Bone Spine. 2019; 86(6):707-713. DOI: 10.1016/j.jbspin.2019.01.016. View

11.

De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A . Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis. 2011; 70(7):1183-90. PMC: 3103668. DOI: 10.1136/ard.2011.150755. View

12.

Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo M . Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood. 2003; 102(3):996-9. DOI: 10.1182/blood-2002-10-3230. View

13.

Passerini M, Schiavini M, Magni C, Landonio S, Niero F, Passerini S . Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience. Eur J Gastroenterol Hepatol. 2018; 30(10):1208-1215. DOI: 10.1097/MEG.0000000000001239. View

14.

Kondili L, Monti M, Quaranta M, Gragnani L, Panetta V, Brancaccio G . A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology. 2021; 76(1):220-232. PMC: 9305531. DOI: 10.1002/hep.32281. View

15.

Lauletta G, Russi S, Pavone F, Vacca A, Dammacco F . Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. Arthritis Res Ther. 2017; 19(1):74. PMC: 5385046. DOI: 10.1186/s13075-017-1280-6. View

16.

Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N . Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology. 2016; 65(5):1770-1771. DOI: 10.1002/hep.28981. View

17.

Saadoun D, Pol S, Ferfar Y, Alric L, Hezode C, Si Ahmed S . Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. Gastroenterology. 2017; 153(1):49-52.e5. DOI: 10.1053/j.gastro.2017.03.006. View

18.

Emery J, Kuczynski M, La D, Almarzooqi S, Kowgier M, Shah H . Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. Am J Gastroenterol. 2017; 112(8):1298-1308. DOI: 10.1038/ajg.2017.49. View

19.

Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas A, Fervenza F, Cacoub P . Cryoglobulinaemia. Nat Rev Dis Primers. 2018; 4(1):11. DOI: 10.1038/s41572-018-0009-4. View

20.

Kayali Z, Buckwold V, Zimmerman B, Schmidt W . Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology. 2002; 36(4 Pt 1):978-85. DOI: 10.1053/jhep.2002.35620. View